<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30118334</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>17</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1751-2441</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>11</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Expert review of clinical pharmacology</Title>                <ISOAbbreviation>Expert Rev Clin Pharmacol</ISOAbbreviation>            </Journal>            <ArticleTitle>Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>833-839</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/17512433.2018.1513321</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Germ line BRCA mutations (gBRCAm) are diagnosed in approximately 5% of unselected breast cancer patients. Olaparib is a new treatment option for patients with a gBRCAm who have metastatic HER2-negative breast cancer. Areas covered: Olaparib is an oral poly (ADP-ribose) polymerase inhibitor that has been shown in phase I-III clinical trials to have single-agent efficacy in breast cancer patients with gBRCAm. The recent phase III OlympiAD study demonstrated a statistically significant progression-free survival benefit compared with the chemotherapy control arm, although an overall survival benefit has not been demonstrated. The most common adverse events seen with olaparib include nausea, anemia, and vomiting. The most common grade 3 adverse events are anemia and neutropenia. Expert commentary: The US FDA-approved olaparib tablets in January 2018 for the treatment of patients with a gBRCAm and metastatic HER2-negative breast cancer. This is a well-tolerated and effective treatment option for this patient population, particularly in patients with triple-negative breast cancer in which chemotherapy is the only alternative. More data are needed to understand the role of olaparib in combination with endocrine therapy, other targeted agents, and chemotherapy, as well as sequentially with platinum chemotherapy in the metastatic setting.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Le</LastName>                    <ForeName>Dan</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Medical Oncology , BC Cancer, Vancouver Centre , Vancouver , Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gelmon</LastName>                    <ForeName>Karen A</ForeName>                    <Initials>KA</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Medical Oncology , BC Cancer, Vancouver Centre , Vancouver , Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>30</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Expert Rev Clin Pharmacol</MedlineTA>            <NlmUniqueID>101278296</NlmUniqueID>            <ISSNLinking>1751-2433</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D024682">BRCA2 Protein</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010793">Phthalazines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000067856">Poly(ADP-ribose) Polymerase Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>WOH1JD9AR8</RegistryNumber>                <NameOfSubstance UI="C531550">olaparib</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D024682" MajorTopicYN="N">BRCA2 Protein</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018095" MajorTopicYN="N">Germ-Line Mutation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010793" MajorTopicYN="N">Phthalazines</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000067856" MajorTopicYN="N">Poly(ADP-ribose) Polymerase Inhibitors</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BRCA</Keyword>            <Keyword MajorTopicYN="N">PARP inhibitor</Keyword>            <Keyword MajorTopicYN="N">metastatic breast cancer</Keyword>            <Keyword MajorTopicYN="N">olaparib</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30118334</ArticleId>            <ArticleId IdType="doi">10.1080/17512433.2018.1513321</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>